Listed

Mesa Laboratories Inc: Form 10-Q for the period ended Dec 31, 2021

Filed with the SEC on Feb 3, 2022 and accepted by EDGAR at Feb 3, 2022, 08:01 ET.

Share

Management's discussion and analysis

As filed, 42,133 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

(Dollars in thousands, except per share amounts)

Forward Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The forward-looking statements in this Quarterly Report on Form 10-Q do not constitute guarantees of future performance. Investors are cautioned that statements in this Quarterly Report on Form 10-Q which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding current or future financial performance and position; potential impairment of future earnings; anticipated effects of, and future actions to be taken in response to, the COVID-19 pandemic; results of acquisitions; management’s strategy, plans and objectives for future operations or acquisitions, product development and sales; product research and development; regulatory approval; selling, general and administrative expenditures; intellectual property; development and manufacturing plans; availability of materials and components; and adequacy of capital resources and financing plans constitute forward-looking statements. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates, and management’s beliefs and assumptions. In addition, other written and oral statements that constitute forward-looking statements may be made by the Company or on the Company’s behalf. Words such as “expect,” “intend,” “seek,” “anticipate,” “believe,” “could,” “estimate,” “plan,” “may,” “target,” “project,” or variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks associated with: the duration and impact of the COVID-19 pandemic and its adverse effects on our business; our ability to successfully grow our business, including as a result of acquisitions; the results on operations of acquisitions; our ability to consummate acquisitions at our historical rate and at appropriate prices, and our ability to effectively integrate acquired businesses and achieve desired results; the market acceptance of our products; technological or market viability of our products; reduced demand for our products; conditions in the global economy and the particular markets we serve; significant developments or uncertainties stemming from governmental actions, including changes in trade policies and medical device regulations; the timely development and commercialization, and customer acceptance, of enhanced and new products and services; retirement of old products and customer migration to new products; projections of revenues, growth, operating results, profit margins, expenses, earnings, margins, tax rates, tax provisions, cash flows, liquidity, demand, and competition; the effects of additional actions taken to become more efficient or lower costs; restructuring activities; laws regulating fraud and abuse in the health care industry and the privacy and security of health and personal information; product liability; information security; outstanding claims, legal and regulatory proceedings; international business challenges including anti-corruption and sanctions laws; tax audits and assessments and other contingent liabilities; foreign currency exchange rates and fluctuations in those rates; general economic, industry, and capital markets conditions; the timing of any of the foregoing; assumptions underlying any of the foregoing; and any other statements that address events or developments that we intend or believe will or may occur in the future. Such risks and uncertainties also include those listed in Item 1A. “Risk Factors” and elsewhere in this report. The foregoing list sets forth many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. We disclaim any obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise.

Business Overview

We are a multinational manufacturer, developer, and seller of life science tools and critical quality control products and services, many of which are sold into niche markets that are driven by regulatory requirements. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe, and Asia Pacific, and by independent distributors in these areas as well as throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross margins. As described in Item 1. Financial Statements Note 12. "Segment Information," during the third quarter of fiscal year 2022, following the acquisition of Agena, Mesa changed its business segment reporting to align with strategic changes in the way we manage our business units. As of December 31, 2021, we managed our operations in four reportable segments, or divisions: Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics, which is comprised of the newly-acquired Agena. Each of our divisions are described further in "Results of Operations" below. Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other.

Corporate Strategy

We strive to create shareholder value and further our purpose of Protecting the Vulnerable® by growing our business both organically and through acquisitions, by improving our operating efficiency, and by continuing to hire, develop and retain top talent. As a business, we commit to our purpose of Protecting the Vulnerable® every day by taking a customer-focused approach to developing, building, and delivering our products. We serve a broad set of industries, in particular the pharmaceutical, healthcare services, and medical device verticals, that require dependable quality control and calibration solutions to ensure the safety and efficacy of the products they use. By delivering the highest quality products possible, we are committed to protecting people, the environment, and end products.

Organic Growth

Organic revenues growth is primarily driven by the expansion of our customer base, increases in sales volumes, and price increases. Our ability to increase organic revenues is affected by general economic conditions, both domestic and international, customer capital spending trends, competition, and the introduction of new products. We typically evaluate costs and pricing annually. Our policy is to price our products competitively and, where possible, we pass along cost increases to our customers in order to maintain our margins.

Gross profit is affected by many factors including our product mix, manufacturing efficiencies, foreign currency rates, and price competition. Historically, as we have integrated our acquisitions and taken advantage of manufacturing efficiencies, our gross profit percentages for some products have improved. There are, however, differences in gross profit percentages between product lines, and ultimately the mix of sales and prices will continue to impact our overall gross profit.

Inorganic Growth - Acquisitions

During the third quarter of fiscal year 2022, we completed the acquisition of Agena for an aggregate purchase price of $300,793, net of cash acquired, subject to customary purchase price adjustments. Agena is a leading clinical genomics tools company that develops, manufactures, and sells highly sensitive, low-cost, high-throughput, genetic analysis tools used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics and oncology. The acquisition of Agena accelerates Mesa's strategic trajectory towards higher growth applications within the regulated segments of the life sciences tools market.

Over the past decade, we have consummated a number of acquisitions as part of our growth strategy. The acquisitions of these businesses have allowed us to expand our product offerings, globalize our company, and increase the scale at which we operate, which in turn affords us the ability to improve our operating efficiency, extend our customer base, and further the pursuit of our purpose: Protecting the Vulnerable®.

Improving Our Operating Efficiency

We maximize value in both our existing businesses and those we acquire by implementing efficiencies in our manufacturing, commercial, engineering, and administrative operations. We achieve efficiencies using the four pillars that make up The Mesa Way, which is our customer-centric, lean-based system for continuously improving and operating a set of high-margin, niche businesses. The Mesa Way is focused on: Measuring What Matters using our customers' perspective and setting high standards for performance; Empowering Teams to improve operationally and exceed customer expectations; Steadily Improving using lean-based tools designed to help us identify the root cause of opportunities and prioritize the biggest opportunities; and Always Learning so that performance continuously improves. As we integrate Agena into our business, we will focus on applying The Mesa Way to its operations which we hope will improve efficiency in some areas of Agena's business.

Hire, Develop, and Retain Top Talent

At the center of our organization are talented people who are capable of taking on new challenges using a team approach. It is our exceptionally talented workforce that works together and uses our lean-based tool set to find ways to continuously improve our products, our services, and ourselves, resulting in long-term value creation for our shareholders.

Business Update and COVID-19

The COVID-19 pandemic began to broadly impact our business late in fiscal year 2020, and its impacts continued to affect our business in various ways throughout fiscal year 2021 and to a lesser extent, into the first three quarters of fiscal year 2022. We continue to monitor the impacts of COVID-19, including the current spread of certain variants of the virus, and we have taken and will continue to take steps to identify and mitigate the adverse impact on, and risks to, our business (including but not limited to our employees, customers, vendors, manufacturing capabilities and capacity, and supply and distribution channels) posed by the spread of COVID-19 and the government responses thereto.

COVID-19 has caused or exacerbated broad market phenomena such as supply chain disruptions, inflation, and wage pressure to which we are susceptible. Each quarter of fiscal year 2022, we have experienced increased supply constraints for certain components used in our operations, particularly components used by the Calibration Solutions division, and to a lesser extent, our Biopharmaceutical Development division; Clinical Genomics has also experienced supply chain constraints although the division has only been part of Mesa since October 20, 2021. We continue to work with our suppliers to understand the existing and potential future impacts to our supply chain and are taking actions in an effort to mitigate such impacts, including pre-ordering components in higher quantities than usual, which has resulted in increased raw materials balances on our balance sheet as of December 31, 2021. The impact of supply chain disruptions is discussed in more detail in our "Results of Operations" and "Risk Factors" below. We expect disruptions to our supply chain to persist at least through fiscal year 2023.

The COVID-19 pandemic and related public health recommendations and mandated precautions to mitigate the spread of the virus, including regulations to close or limit the operating hours of our laboratory and facilities of our customers, and to prevent non-essential personnel from going on-site to customer locations to service or market our products, have negatively affected our operations. While many recommendations and precautions that affected us in fiscal year 2021 have been rescinded in the United States, some restrictions were reimposed for portions of the nine months ended December 31, 2021 as COVID-19 variants spread widely. Our operations in Europe and Asia have been most impacted because regulations and restrictions have tended to be more widespread in those areas. In contrast to the negative impacts experienced by our other divisions, our Clinical Genomics division produces a consumable reagent that can be used with its proprietary MassARRAY® instruments to accurately identify the presence of the COVID-19 virus and identify the variant from a biological sample. As a result, the Clinical Genomics division has benefited to some extent from outbreaks and resulting increased testing efforts. However, like in our other divisions, regulatory restrictions, particularly in Asia have negatively impacted commercial execution, limiting sales of all types of Clinical Genomics instruments to new customers.

Sales of our hardware products have historically been more sensitive to general economic conditions than sales of our consumables. This pattern was apparent during fiscal year 2021 and continued into the first quarter of fiscal year 2022. In addition, even after the COVID-19 pandemic has subsided as a public health matter, we may experience material adverse impacts to our business as a result of its adverse impact on the global economy, in-person collaboration and sales efforts, and our customers’ changed purchasing behavior and confidence.

Results of Operations

Our results of operations and period-over-period changes are discussed in the following section. The tables and discussion below should be read in conjunction with the accompanying Unaudited Condensed Consolidated Financial Statements and the notes thereto appearing in Item 1. Financial Statements (in thousands, except percent data).

Revenues from our reportable segments increased 60% and 31% for the three and nine months ended December 31, 2021, respectively. Revenues growth was primarily attributable to the acquisition of Agena; however, organic revenues growth was 12% and 14% for the three and nine months ended December 31, 2021, respectively. Gross profit as a percentage of revenues decreased eight and six percentage points for the three and nine months ended December 31, 2021, respectively, compared to the three and nine months ended December 31, 2020, respectively, primarily as a result of amortization of the inventory step-up of $6,062 as required by purchase accounting. Results by reportable segment are as follows:

Revenues Three Months Ended December 31, 2021 Three Months Ended December 31, 2020 Organic Revenues Growth Three Months Ended December 31, 2021 Three Months Ended December 31, 2020 Gross Profit as a % of Revenues Three Months Ended December 31, 2021 Three Months Ended December 31, 2020
Sterilization and Disinfection Control $13,831 $13,077 6% 13% 72% 71%
Biopharmaceutical Development 12,756 8,711 46% 14% 69% 53%
Calibration Solutions 11,624 12,384 (6%) (13%) 52% 55%
Clinical Genomics 16,485 - N/A N/A 24% N/A
Mesa Labs' reportable segments $54,696 $34,172 12% 1% 53% 61%
Revenues Nine Months Ended December 31, 2021 Nine Months Ended December 31, 2020 Organic Revenues Growth Nine Months Ended December 31, 2021 Nine Months Ended December 31, 2020 Gross Profit as a % of Revenues Nine Months Ended December 31, 2021 Nine Months Ended December 31, 2020
Sterilization and Disinfection Control $43,014 $37,696 14% 5% 74% 75%
Biopharmaceutical Development 32,188 23,791 35% 14% 62% 64%
Calibration Solutions 33,769 34,486 (2%) (13%) 54% 55%
Clinical Genomics 16,485 - N/A N/A 24% N/A
Mesa Labs' reportable segments $125,456 $95,973 14% (3%) 59% 65%

Our unaudited condensed consolidated results of operations are as follows:

Three Months Ended December 31, 2021 2020 Percentage Change Nine Months Ended December 31, 2021 2020 Percentage Change
Revenues $54,696 $34,172 60% $125,456 $95,973 31%
Gross profit 28,627 20,653 39% 73,978 62,278 19%
Operating expenses 31,139 20,631 51% 69,166 54,216 28%
Operating (loss) income (2,512) 22 (11,518%) 4,812 8,062 (40%)
Net (loss) income $(2,060) $(4,542) (55%) $3,655 $(646) (666%)

Reportable Segments

Sterilization and Disinfection Control

Our Sterilization and Disinfection Control division manufactures and sells biological, cleaning, and chemical indicators which are used to assess the effectiveness of sterilization and disinfection processes in the hospital, medical device, and pharmaceutical industries. The division also provides testing and laboratory services, mainly to the dental industry. Sterilization and disinfection control products are disposable and are used on a routine basis.

Three Months Ended December 31, 2021 2020 Percentage Change Nine Months Ended December 31, 2021 2020 Percentage Change
Revenues $13,831 $13,077 6% $43,014 $37,696 14%
Gross profit 9,945 9,308 7% 31,859 28,098 13%
Gross profit as a % of revenues 72% 71% 1% 74% 75% (1%)

Sterilization and Disinfection Control revenues increased 6% and 14% for the three and nine months ended December 31, 2021, respectively, which was achieved through effective efforts by our sales team to market and sell certain products to a larger customer base. Additionally, revenues increases were attributable to volume increases with existing customers, particularly in the healthcare and biopharmaceutical markets, partially offset by a strengthening of the U.S. dollar against the euro.

Sterilization and Disinfection Control's gross profit percentage increased one percentage point for the three months ended December 31, 2021, primarily as a result of production efficiencies resulting from higher revenues and favorable product mix, partially offset by unfavorable exchange rates. Gross profit percentage decreased one percentage point for the nine months ended December 31, 2021 as a result of unfavorable product mix and slightly higher production costs, and to a lesser extent, unfavorable exchange rates.

Biopharmaceutical Development

Our Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Immunoassays and peptide synthesis solutions accelerate the discovery, development, and manufacturing of biotherapeutic drugs.

Three Months Ended December 31, 2021 2020 Percentage Change Nine Months Ended December 31, 2021 2020 Percentage Change
Revenues $12,756 $8,711 46% $32,188 $23,791 35%
Gross profit 8,768 4,616 90% 20,061 15,294 31%
Gross profit as a % of revenues 69% 53% 16% 62% 64% (2%)

Biopharmaceutical Development revenues increased 46% and 35% for the three and nine months ended December 31, 2021, respectively, primarily due to increased sales of consumables as our laboratory customers were open for more normal operating hours in the first three quarters of fiscal year 2022 compared to the first three quarters of fiscal year 2021, growing adoption in the cell and gene therapy market, and resumed in-person marketing efforts which resulted in higher hardware sales. Biopharmaceutical Development also benefited from more customers allowing in-person visits at certain times during the nine months ended December 31, 2021, which enabled us to complete more service visits and to more effectively market our products in person.

Biopharmaceutical Development's gross profit percentage increased 16 percentage points for the third quarter of fiscal year 2022 compared to the third quarter of fiscal year 2021 as a result of a favorable change in foreign exchange rates as well as production efficiencies resulting from increased revenues, and a favorable mix shift towards immunoassay products, partially offset by higher labor costs. Biopharmaceutical Development's gross profit percentage decreased two percentage points for the nine months ended December 31, 2021 as a result of the benefit of a positive $258 purchase accounting adjustment in the nine months ended December 31, 2020, higher labor-related costs, and to a lesser extent, net unfavorable changes in foreign exchange rates.

Substantially all of this division's sales are invoiced in either euros or U.S. dollars ("USD"); however, the majority of the costs in this division are recorded in Swedish Krona ("SEK") and translated to USD for reporting purposes. During periods in which the USD is weaker against the SEK, such as in the first and second quarters of fiscal year 2022, our USD reported costs are inflated and gross profit is lower. In periods in which the USD strengthens against the SEK, such as in the third quarter of fiscal year 2022, our USD reported costs are lower and gross profit is higher.

Calibration Solutions

This new reportable segment is comprised of the historical Instruments and Continuous Monitoring reportable segments. The Calibration Solutions division designs, manufactures, and markets quality control and calibration products used to measure or calibrate temperature, pressure, pH, humidity, and other such parameters for health and safety purposes, primarily in hospital, medical device manufacturing, pharmaceutical, and laboratory environments.

Three Months Ended December 31, 2021 2020 Percentage Change Nine Months Ended December 31, 2021 2020 Percentage Change
Revenues $11,624 $12,384 (6%) $33,769 $34,486 (2%)
Gross profit 6,090 6,869 (11%) 18,330 18,962 (3%)
Gross profit as a % of revenues 52% 55% (3%) 54% 55% (1%)

Calibration Solutions division revenues decreased 6% and 2% for the three and nine months ended December 31, 2021, respectively, primarily as a result of supply and labor constraints limiting our ability to manufacture ordered quantities of certain products, partially offset by higher service revenues as our service technicians were able to go to client sites to complete service requests and hardware installations as COVID-19 related restrictions were partially lifted. Despite fulfillment delays for many customer orders, demand for the division's products has continued to increase through fiscal year 2022 and to date, we have been able to retain the significant majority of our customers and orders.

The Calibration Solutions division's gross profit percentage decreased three percentage points and one percentage point during the three and nine months ended December 31, 2021, respectively. The decrease in gross profit percentage resulted from lower revenues on a partially fixed cost base, increased freight on purchased components, and higher labor costs as a result of a strong competition for employees in the labor market. Supply chain disruptions and higher labor costs are expected to continue through fiscal year 2023.

Clinical Genomics

This is a new reportable segment comprised of the recently acquired Agena. The Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput, genetic analysis tools used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics and oncology.

Three Months Ended December 31, 2021 2020 Percentage Change Nine Months Ended December 31, 2021 2020 Percentage Change
Revenues $16,485 $- N/A $16,485 $- N/A
Gross profit 3,924 - N/A 3,924 - N/A
Gross profit as a % of revenues 24% N/A N/A 24% N/A N/A

Revenues in the Clinical Genomics division represent revenues from October 20, 2021 until December 31, 2021. Of the revenues reported, $1,500 represents revenues from COVID-19-related sales of which the substantial majority are consumables.

Clinical Genomics gross profit was $3,924 for the period from October 20, 2021 until December 31, 2021. Gross profit includes $6,062 of amortization on an inventory step-up recorded in purchase accounting related to the Agena Acquisition. Excluding the step-up amortization, gross profit for the period ended December 31, 2021 would have been $9,986, and gross profit as a percentage of revenues would have been 61%. Gross profit also includes $911 of amortization of intellectual property from the Agena Acquisition. Going forward, we expect gross profit as a percentage of revenues to range from the high 50s to the low 60s, including a quarterly impact of $1,155 of non-cash amortization of intellectual property.

Operating Expenses

Operating expenses increased 51% and 28% for the three and nine months ended December 31, 2021 compared to the three and nine months ended December 31, 2020, respectively, as a result of the Agena Acquisition and as our overall business grew.

Selling

Selling expense is driven primarily by labor costs, including salaries and commissions; accordingly, it may vary with sales levels.

Three Months Ended December 31, 2021 2020 Percentage Change Nine Months Ended December 31, 2021 2020 Percentage Change
Selling expense $8,958 $4,753 88% $18,459 $12,614 46%
As a percentage of revenues 16% 14% 2% 15% 13% 2%

Selling expense for the three and nine months ended December 31, 2021 increased 88% and 46%, respectively, primarily as a result of the acquisition of Agena. Excluding the impact of Agena, selling expense increased 16% and 18% for the three and nine months ended December 31, 2021, as we executed on our previously-announced plan to invest in sales and marketing resources in order to increase organic revenues growth. We have hired several sales employees throughout fiscal year 2022, resulting in higher labor-related costs, including accruing commissions on higher sales. Further, travel-related costs increased because we resumed some in-person sales events as restrictions on gatherings lifted compared to fiscal year 2021. Including the acquisition of Agena and its sales force, we expect total selling expense will approximate 16% to 18% of revenues for fiscal year 2023.

General and Administrative

Labor costs, including non-cash stock-based compensation, and amortization of intangible assets drive the substantial majority of our general and administrative expense.

Three Months Ended December 31, 2021 2020 Percentage Change Nine Months Ended December 31, 2021 2020 Percentage Change
General and administrative expense $17,017 $13,173 29% $40,119 $33,887 18%
As a percentage of revenues 31% 39% (8%) 32% 35% (3%)

General and administrative expenses increased 29% and 18% for the three and nine months ended December 31, 2021, respectively, primarily as a result of the acquisition of Agena. Excluding the impact of Agena, general and administrative expenses increased 9% and 10% for the three and nine months ended December 31, 2021.

Excluding Agena, the increase in general and administrative costs for the third quarter of fiscal year 2022 was a result of higher bonus accruals based on our financial results for the nine months ended December 31, 2021 and costs associated with the Agena Acquisition, partially offset by lower stock-based compensation expense due to a $1,629 cumulative effect true up related to certain performance stock units recorded during the third quarter of fiscal year 2021. For the nine months ended December 31, 2021, the increase in general and administrative costs excluding Agena was a result of higher stock-based compensation expense as we expanded the number of participants in our stock based compensation programs, increased bonus expense, costs associated with the Agena Acquisition, and increased amortization costs resulting from a $344 cumulative effect decrease to amortization expense recorded during the first quarter of fiscal year 2021 as part of a purchase price adjustment.

Research and Development

Research and development expense is predominantly comprised of labor costs and costs of third-party consultants.

Three Months Ended December 31, 2021 2020 Percentage Change Nine Months Ended December 31, 2021 2020 Percentage Change
Research and development expense $5,164 $2,705 91% $10,588 $7,715 37%
As a percentage of revenues 9% 8% 1% 8% 8% -%

Research and development expenses increased 91% and 37% for the three and nine months ended December 31, 2021, respectively, primarily as a result of the acquisition of Agena. Excluding the impact of Agena, research and development costs for the three and nine months ended December 31, 2021 increased 21% and 13%, respectively, primarily as a result of higher personnel and third-party contractor expenditures supporting our continued incremental investments in enhancing existing products as well as the development of new products and features. We expect research and development expenses will approximate 9% to 12% of revenues for fiscal year 2023.

Nonoperating Expense

Three Months Ended December 31, 2021 2020 Percentage Change Nine Months Ended December 31, 2021 2020 Percentage Change
Nonoperating (income) expense $(171) 5,749 (103%) $1,192 $10,651 (89%)

Nonoperating (income) expense for the three and nine months ended December 31, 2021 is composed primarily of interest expense and amortization of the debt discount associated with the Notes and gains and losses on foreign currency transactions.

We recorded net unrealized gains on foreign currency which were primarily related to the movement of the SEK against the USD on certain intercompany notes. Foreign currency gains were partially offset by interest expense and amortization of debt discount on the Notes and the Credit Facility. Interest expense and amortization of debt discount decreased for the three and nine months ended December 31, 2021 compared to the three and nine months ended December 31, 2020 due to our adoption of ASU 2020-06, which resulted in a reduction in non-cash interest expense related to the Notes.

Income Taxes

Three Months Ended December 31, 2021 2020 Percentage Change Nine Months Ended December 31, 2021 2020 Percentage Change
Income tax provision (benefit) $(281) $(1,185) (76%) $(35) $(1,943) (98%)
Effective tax rate 12% 21% (9%) (1%) 75% (76%)

Our effective tax rate benefited notably from the exercise of stock options and, to a lesser extent, the benefit of federal derived intangible income, partially offset by the limitations imposed by Section 162(m) and higher state income taxes. Our income tax rate varies based upon many factors, but in general, we anticipate that on a go-forward basis our effective tax rate will be approximately 26%, plus or minus the impact of excess tax benefits and deficiencies associated with share-based payment awards to employees; see Note 9. “Income Taxes” within Item 1. Financial Statements for additional discussion. The excess tax benefits and deficiencies associated with share-based payment awards to our employees have caused and, in the future, may cause large fluctuations in our realized effective tax rate based on timing, volume, and nature of stock options exercised under our share-based payment program.

Net Income

Net income for the nine months December 31, 2021 varied with the changes in revenues, gross profit, and operating expenses (and included $13,495, $7,939, and $6,062 of non-cash amortization of intangible assets acquired in a business combination, stock-based compensation expense, and amortization of inventory step-up, respectively). Prior to the adoption of ASU 2020-06 on April 1, 2021, we were required to recognize non-cash interest expense related to the amortization of debt discounts and issuance costs. Subsequent to the adoption, we recognize non-cash interest expense related to amortization of debt issuance costs only, resulting in higher net income subsequent to the adoption of ASU 2020-06.

Liquidity and Capital Resources

Our sources of liquidity include cash generated from operations, cash and cash equivalents on hand, cash available from our Credit Facility, working capital and potential additional equity and debt offerings. Despite lingering uncertainties surrounding the economic impacts of the COVID-19 pandemic, we continue to believe that we have the liquidity required to continue operations even if volatility in the economic environment reoccurs. We believe that cash and cash equivalents on hand and cash generated from operations, as well as the remainder of the unused capacity under our Credit Facility, will be sufficient to meet our short-term and long-term needs.

Our more significant uses of resources have historically included acquisitions, long-term capital expenditures, payments of debt and interest obligations, and quarterly dividends to shareholders. Working capital is the amount by which current assets exceed current liabilities. We had working capital of $74,220 and $271,166 as of December 31, 2021 and March 31, 2021, respectively. As of December 31, 2021, and March 31, 2021, we had $51,706 and $263,865, respectively, of cash and cash equivalents; at March 31, 2021, the cash was primarily held in money market funds. We consider all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.

We completed the acquisition of Agena for an adjusted purchase price, net of cash acquired, of $300,793 during the third quarter of fiscal year 2022.

During fiscal year 2021, we entered into the Credit Facility, a four-year senior secured credit agreement that includes 1) a revolving credit facility in an aggregate principal amount of up to $75,000, 2) a swingline loan in an aggregate principal amount not exceeding $5,000, and 3) letters of credit in an aggregate stated amount not exceeding $2,500 at any time. The Credit Facility also provides for an incremental term loan or an increase in revolving commitments in an aggregate principal amount of at a minimum $25,000 and at a maximum $75,000, subject to the satisfaction of certain conditions and lender considerations. During the third quarter of fiscal year 2022, we borrowed $70,000 under our line of credit to fund the acquisition of Agena, and we repaid $10,000 using cash on hand and cash generated from operations. As of December 31, 2021, we had $15,000 remaining available to draw on the Credit Facility. In January 2022, we repaid $4,000 of the amount outstanding under the Credit Facility.

As of December 31, 2021, $172,500 in aggregate principal Notes was outstanding. The Notes bear interest at a rate of 1.375% payable semi-annually in arrears on February 15 and August 15 of each year, beginning with our first payment made on February 15, 2020. The Notes can be converted by holders prior to maturity if certain conditions are met, but none of those conditions were met during fiscal year 2022. We currently expect to settle future conversions of the Notes entirely in shares of our common stock and will reevaluate this policy from time to time in the event that conversion conditions are met and conversion notices are received from holders of the Notes. We were in compliance with all debt agreements as of December 31, 2021 and for all prior years presented and have met all debt payment obligations. Refer to Note 6. "Indebtedness" within Item 1. Financial Statements for more detail.

We routinely evaluate opportunities for strategic acquisitions. Future material acquisitions may require that we obtain additional capital, assume additional third-party debt or incur other long-term obligations. We believe that we have the ability to issue more equity or debt in the future in order to finance our acquisition and investment activities; however, additional equity or debt financing, or other transactions, may not be available on acceptable terms, if at all.

We may from time to time repurchase or take other steps to reduce our debt. These actions may include retirements or refinancing of outstanding debt, privately negotiated transactions or otherwise. The amount of debt that may be retired, if any, could be material and would be decided at the sole discretion of our Board of Directors and would depend on market conditions, our cash position, and other considerations.

Dividends

We have paid regular quarterly dividends since 2003. We declared and paid dividends of $0.16 per share during each of the quarters ended June 30, 2021, September 30, 2021, and December 31, 2021, as well as each quarter of fiscal year 2021.

In January 2022, we announced that our Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, payable on March 15, 2022, to shareholders of record at the close of business on February 28, 2022.

Cash Flows

Our cash flows from operating, investing, and financing activities were as follows (in thousands):

Nine Months Ended December 31, 2021 2020
Net cash provided by operating activities $29,921 $23,553
Net cash (used in) investing activities (304,443) (954)
Net cash provided by financing activities 62,623 147,275

Cash flows from operating activities for the nine months ended December 31, 2021 provided $29,921. The $6,368 increase in cash flows from operating activities primarily resulted from non-cash adjustments to net income, particularly amortization of the inventory step-up associated with the Agena Acquisition, and to a lesser extent, increased depreciation and amortization as a result of higher intangibles balances resulting from the Agena Acquisition, as well as increased net income. Further, cash provided by operating assets and liabilities increased by $778 for the nine months ended December 31, 2021 compared to the nine months ended December 31, 2020, primarily as a result of the impact of timing on our working capital accounts. Cash used in investing activities was higher during the nine months ended December 31, 2021 compared to the nine months ended December 31, 2020, due to cash expended on the Agena Acquisition, and to a lesser extent purchases of property, plant, and equipment, primarily to support the renovations of our Lakewood, Colorado facility. Cash provided by financing activities primarily resulted from a $70,000 draw on our Credit Facility, net of $10,000 repaid during the quarter. The draw on our Credit Facility was used to fund a portion of the purchase price of the Agena Acquisition. Our equity raise completed during the nine months ended December 31, 2020 provided $145,935.

Contractual Obligations and Other Commercial Commitments

We are party to many contractual obligations that involve commitments to make payments to third parties in the ordinary course of business. For a description of our contractual obligations and other commercial commitments as of March 31, 2021, see our Annual Report on Form 10-K for the fiscal year ended March 31, 2021, filed with the Securities and Exchange Commission on June 1, 2021. As a result of the Agena Acquisition in the third quarter of fiscal year 2022, we have assumed certain contractual obligations, including an additional $9,884 of payments under existing lease agreements, and $4,564 of open purchase orders as of December 31, 2021.

On a consolidated basis, at December 31, 2021, we had contractual obligations for open purchase orders of approximately $18,852 for routine purchases of supplies and inventory, which are payable in less than one year. Open purchase orders continue to increase as we take proactive steps to mitigate risks in supply by increasing our orders of certain critical raw materials.

Off-Balance Sheet Arrangements

As of December 31, 2021, we had no off-balance sheet arrangements or obligations.

Critical Accounting Policies and Estimates

Critical accounting estimates are those that we believe are both significant and require us to make difficult, subjective, or complex judgments, often because we need to estimate the effect of inherently uncertain matters. These estimates are based on historical experience and various other factors that we believe to be appropriate under the circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended March 31, 2021, in the Critical Accounting Policies and Estimates section of Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Market risk

As filed, 1,771 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our reporting currency is U.S. dollars, and the functional currency of each of our material foreign subsidiaries is its respective local currency. Our operations include activities outside of the U.S. and we have currency risk on the transactions in other currencies and translation adjustments resulting from the conversion of our international financial results into the U.S. dollar. We face currency exposures in our global operations as a result of various factors including intercompany currency denominated loans, selling our products in various currencies, purchasing raw materials and equipment in various currencies, and tax exposures not denominated in the functional currency. These exposures have increased as we have continued to expand internationally, including the acquisition of GPT, which conducts a substantial portion of its business expenses in Swedish Krona and the acquisition of Agena, which conducts a portion of its business in Chinese Yuan. Fluctuations in exchange rates have and may continue to adversely affect our results of operations, financial position, and cash flows. We do not hedge exposure to exchange rates.

We have in the past held investments in money market funds. As a result, we have been exposed to potential loss from market risks that may occur as a result of changes in interest rates, credit quality of the issuer, or other factors. Our Credit Facility bears interest at either a base rate or a Eurodollar rate, plus an applicable spread. Based on the balance currently outstanding against our line of credit, if interest rates increased by 75 basis points, we would incur approximately $420 of additional interest expense per year.

We have no derivative instruments. We have minimal exposure to commodity market risks.

Controls and procedures

As filed, 2,562 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) that are designed to ensure that information required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Evaluation of Disclosure Controls and Procedures

As of December 31, 2021, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

Changes in Internal Control over Financial Reporting

The Agena Acquisition was completed on October 20, 2021. The financial results of Agena are included in our unaudited consolidated financial statements as of December 31, 2021 and for the quarter then ended. The Agena business represented approximately $16,485 to revenues and ($4,532) of net loss for the third quarter of fiscal year 2022. As this acquisition occurred in the third quarter of fiscal year 2022, the scope of our assessment of our internal control over financial reporting does not include Agena. This exclusion is in accordance with the Securities and Exchange Commission’s general guidance that an assessment of a recently acquired business may be omitted from our scope in the year of acquisition.

During the second quarter of fiscal year 2022, we implemented a new human resources information and payroll system, which is considered to be a key system as part of our internal controls over financial reporting. We continued to integrate the software with our processes, systems, and controls in the third quarter of fiscal year 2022. There were no other changes during the quarter ended December 31, 2021 in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

Risk factors

As filed, 2,365 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We are dependent on our suppliers to deliver components, and a shortage of and increasing prices of components have and could continue to disrupt our production and delay order fulfillment.

Products we sell are made of components, including electronic components, glass, plastics, and packaging that we source globally from suppliers who, in turn, source components from their suppliers. If there is a shortage of a key component in our supply chain, and the component cannot be easily sourced from a different supplier, the shortage may disrupt our production which may, in turn, delay order fulfillment. We are experiencing long lead times, and in some cases, difficulty obtaining components from our existing suppliers, which has resulted in delayed order fulfillment to varying degrees in our divisions, especially the Calibration Solutions, Biopharmaceutical Development, and Clinical Genomics divisions. In addition, costs for components and transportation costs have increased, which may reduce our gross profit margins unless and until we are able to pass the cost increases along to our customers. There are several reasons for the supply chain disruptions to components that we rely on to manufacture our products, including: increased demand for other products that use the same components as those we purchase, manufacturing shut-downs during the past 18 months that reduced production of components, obsolescence of materials we have historically purchased, labor issues, and long lead times for raw materials used in the production of components. A continued shortage of components or other key materials that comprise the components could cause a significant disruption to our production schedule and have a substantial adverse effect on our financial condition or results of operations.

Additional risks related to our supply chain include those in our fiscal year 2021 Form 10-K risk factors, “We face numerous manufacturing and supply chain risks. In addition, our reliance upon sole or limited sources of supply for certain materials, components and services could cause production interruptions, delays and inefficiencies.”

During the third quarter of fiscal year 2022, there were no other material changes from the risk factors described in Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended March 31, 2021.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2021-10-01 to 2021-12-31$54.7mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2021-04-01 to 2021-12-31$125.5mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2021-10-01 to 2021-12-31$26.1mus-gaap:CostOfRevenue
Cost of revenue9 months2021-04-01 to 2021-12-31$51.5mus-gaap:CostOfRevenue
Gross profit3 months2021-10-01 to 2021-12-31$28.6mus-gaap:GrossProfit
Gross profit9 months2021-04-01 to 2021-12-31$74.0mus-gaap:GrossProfit
Research and development3 months2021-10-01 to 2021-12-31$5.2mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2021-04-01 to 2021-12-31$10.6mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2021-10-01 to 2021-12-31−$2.5mus-gaap:OperatingIncomeLoss
Operating income9 months2021-04-01 to 2021-12-31$4.8mus-gaap:OperatingIncomeLoss
Interest expense3 months2021-10-01 to 2021-12-31$1.0mus-gaap:InterestExpense
Interest expense9 months2021-04-01 to 2021-12-31$2.6mus-gaap:InterestExpense
Income tax3 months2021-10-01 to 2021-12-31−$281.0kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2021-04-01 to 2021-12-31−$35.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2021-10-01 to 2021-12-31−$2.1mus-gaap:NetIncomeLoss
Net income9 months2021-04-01 to 2021-12-31$3.7mus-gaap:NetIncomeLoss
Diluted EPS3 months2021-10-01 to 2021-12-31−$0.39us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2021-04-01 to 2021-12-31$0.69us-gaap:EarningsPerShareDiluted
Basic EPS3 months2021-10-01 to 2021-12-31−$0.39us-gaap:EarningsPerShareBasic
Basic EPS9 months2021-04-01 to 2021-12-31$0.70us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2021-10-01 to 2021-12-315,233,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2021-04-01 to 2021-12-315,333,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2021-04-01 to 2021-12-31$29.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2021-04-01 to 2021-12-31$3.6mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid9 months2021-04-01 to 2021-12-31$2.5mus-gaap:PaymentsOfDividends
Cash and equivalentsAt period end2021-12-31$51.7mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2021-12-31$121.0mus-gaap:AssetsCurrent
Total assetsAt period end2021-12-31$721.7mus-gaap:Assets
Current liabilitiesAt period end2021-12-31$46.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2021-12-31$325.4mus-gaap:Liabilities
Shareholders' equityAt period end2021-12-31$396.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001437749-22-002291. Last ingested by Listed: Nov 13, 2026, 07:45 ET. Listed shows no prices and gives no investment advice.